ABSTRACT
Wastewater-based surveillance systems can track trends in multiple pathogens simultaneously by leveraging efficient, streamlined laboratory processing. In Switzerland, wastewater surveillance is conducted for fourteen locations representing 2.3 million people, or 26% of the national population, with simultaneous surveillance of four respiratory pathogens. Trends in respiratory diseases are tracked using a novel, six-plex digital PCR assay targeting Influenza A, Influenza B, Respiratory Syncytial Virus, and SARS-CoV-2 N1 and N2 genes, as well as Murine Hepatitis Virus for recovery efficiency control. The multiplex assay was developed to ensure sensitivity and accurate quantification for all targets simultaneously. Wastewater data is also integrated with disease data obtained through both a mandatory disease reporting system and the Swiss Sentinel System (Sentinella), a voluntary reporting system for general practitioners. Comparisons between wastewater data and case data from July 2023 through July 2024 demonstrate a high level of agreement, specifically for Influenza A, SARS-CoV-2, and Respiratory Syncytial Virus. Lower correspondence is observed for Influenza B, which highlights challenges in tracking disease dynamics during seasons without pronounced outbreak periods. Wastewater monitoring further revealed that targeting the N1 or N2 gene led to divergent estimates of SARS-Cov-2 viral loads, highlighting the impact of mutations in the target region of the assay on tracking trends. The study emphasizes the importance of an integrated wastewater monitoring program as a complementary tool for public health surveillance by demonstrating clear concordance with clinical data for respiratory pathogens beyond SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Swiss National Science Foundation (SNSF Sinergia Grant Nr. CRSII5_205933) and by the Swiss Federal Office of Public Health grant to CO and TRJ. Some data and figures from the manuscript presented here have been used to create a report to the primary funding body, the Swiss Federal Office of Public Health. The report was briefly made public (September to November 2024).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Weekly case data are available from the Federal Office of Public Health (FOPH) via a public API (https://api.idd.bag.admin.ch/swagger-ui/api-doc.html). Daily case data are available on request to the FOPH and were used only for the purpose of correlation coefficient analyses. The datasets used in our study contain only aggregated data (no individual-level data have been used).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
